Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jul;23(3):853-858.
doi: 10.1007/s10238-022-00842-z. Epub 2022 Jun 23.

Beta-adrenergic receptor blockers and hepatocellular carcinoma survival: a systemic review and meta-analysis

Hyun Chang  1 , Sung Hyun Lee  2
Affiliations
Meta-Analysis

Beta-adrenergic receptor blockers and hepatocellular carcinoma survival: a systemic review and meta-analysis

Hyun Chang et al. Clin Exp Med. 2023 Jul.

Abstract

Introduction: Preclinical data have revealed that beta-adrenergic stimulation can affect the growth and progression of different types of malignancies. Beta-adrenergic receptor blockers have been associated with improved survival in patients with many types of cancer. We performed a meta-analysis to investigate the association between beta-blocker use and hepatocellular carcinoma (HCC) prognosis.

Methods: In this meta-analysis, a full search was conducted using PubMed, the Cochrane library and Embase to identify all relevant studies published up to May 2021. Available hazard ratios (HRs) were extracted for overall survival (OS), cancer-specific survival (CSS) and pooled using a random-effects meta-analysis.

Results: Four studies involving 7252 patients with HCC met the inclusion criteria and were included in the systemic review. Three studies that reported OS data of 5148 patients were included in the meta-analysis. The random-effects model showed that beta-blocker use was associated with significantly improved OS in HCC (HR = 0.69, 95% CI = 0.54-0.88, P = 0.0031), without significant heterogeneity (I2 = 41%; Q = 6.42, P = 0.18).

Conclusion: This meta-analysis suggested that beta-blocker use can be associated with prolonged OS of patients with HCC.

Keywords: Beta-blocker; Hepatocellular carcinoma; Meta-analysis; Survival.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020;72:250–61. https://doi.org/10.1016/j.jhep.2019.08.025 . - DOI - PubMed - PMC
    1. Nault JC, Sutter O, Nahon P, et al. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. J Hepatol. 2018;68:783–97. https://doi.org/10.1016/j.jhep.2017.10.004 . - DOI - PubMed
    1. Palmer DH. Radiofrequency ablation with or without transcatheter arterial chemoembolization. J Clin Oncol. 2013;31:2756. https://doi.org/10.1200/JCO.2013.49.8352 . - DOI - PubMed
    1. Koulouris A, Tsagkaris C, Spyrou V, et al. Hepatocellular carcinoma: an overview of the changing landscape of treatment options. J Hepatocell Carcinoma. 2021;8:387–401. https://doi.org/10.2147/JHC.S300182 . - DOI - PubMed - PMC
    1. Quaglia A. Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist. J Hepatocell Carcinoma. 2018;5:99–108. https://doi.org/10.2147/JHC.S159808 . - DOI - PubMed - PMC

Substances

LinkOut - more resources